BRCA1 and familial pancreatic carcinoma: Recently, cancer genetic predisposition and precision medicine have found a contact point, thanks to the discovery of the therapeutic potential of PARP inhibitors in BRCA1/2 PV/LPV carriers [288,289], at first in OC [290] and then in BC, prostate, and pancreatic cancers [291,292,293].